FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE) reported that ground has been broken for new facilities for its joint venture in the People’s Republic of China (PRC). The joint venture, named Unigene Biotechnology Co. Ltd. (JV), will operate facilities for research, development, formulation and manufacturing that will occupy more than 215,000 square feet on land made available to the JV by Unigene’s original JV partner, the Shijiazhuang Pharmaceutical Group Corporation (SPG) and its subsidiaries the China Pharmaceutical Group Ltd. (CPG), a publicly traded company based in Hong Kong, and NBP Pharmaceutical Company Ltd. (NBP). The location of the park is in the Shijiazhuang Economic and Technology Development Zone of Hebei Province. Ground-breaking ceremonies were held last week at the site and were attended by provincial and local government officials including the deputy mayor of Shijiazhuang, executives from the partner companies, local dignitaries and more than one hundred guests.
